Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    VVUS

Delayed Quote. Delayed  - 09/29 10:00:00 pm
1.13 USD   -3.42%
08/29 VIVUS : Extends Return Date of STENDRA Commercial Rights
08/18 VIVUS : Biotech Stocks on Investors' Radar -- Illumina, XOMA, Lexico..
08/04 VIVUS : reports 2Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

VIVUS, Inc. : Trending News: VIVUS, SunTrust Banks, SAP AG, Google Inc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:15pm CEST

NEW YORK, April 19, 2013 - cheapstocks.us, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on VIVUS, SunTrust Banks, SAP AG, Google Inc.

VIVUS, Inc.(NASDAQ:VVUS) shares gained 3.97% to $12.57. The company on April 16 announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia® (phentermine and topiramate extended-release) capsules CIV. The amendment, submitted in October 2012, allows Qsymia to be dispensed through certified retail pharmacies, in addition to the existing network of certified mail-order pharmacies.

Is This A Turn Around New For VVUS? Get Free Report Here http://cheapstocks.us/index-lp2-aw.php?code=VVUS (OR Just copy and paste the link)

SunTrust Banks, Inc. (NYSE:STI) shares gained 1.72% to $27.71. The company on April 19, posted first quarter net income of $340 million from $245 million last year. Earnings per share grew 37 percent to $0.63 from $0.46 a year ago. Analysts expected the company to report earnings of $0.61 per share for the quarter. Total revenue, on a fully taxable-equivalent or FTE basis, dropped 5 percent to $2.114 billion. Revenue decreased 4 percent to $2.112 billion. Analysts had consensus revenue estimate of $2.25 billion for the quarter.

What Should Be The Fair Value Of STI After The Earnings? Find Out Here http://cheapstocks.us/index-lp2-aw.php?code=STI (OR Just copy and paste the link)

SAP AG (ADR)(NYSE:SAP) shares decreased 2.08% to $76.55. The company, on April 19, announced its financial results for the first quarter ended March 31, 2013. The company had a solid start to 2013 with 23% (25% at constant currencies) growth in non-IFRS software and cloud subscription revenue. SAP achieved ?824 million in non-IFRS software and cloud subscription revenue in the first quarter.

How Should investors Trade Sap After The Earnings? Get Free Trend Analysis Here http://cheapstocks.us/index-lp2-aw.php?code=SAP (OR Just copy and paste the link)

Looking forward, the company expects fiscal 2013 non-IFRS software and cloud subscription revenue to increase in a range of 14%-20% at constant currencies (fiscal 2012: EUR5.00 billion). The fiscal 2013 non-IFRS
cloud subscription and support revenue contributing to this growth is expected to be around EUR750 million at constant currencies (fiscal 2012: EUR343 million). The Company expects fiscal 2013 non-IFRS software and
software-related service revenue to increase in a range of 11%-13% at constant currencies (fiscal 2012: EUR13.25 billion).

Google Inc(NASDAQ:GOOG) shares increased 0.79% to $772. The company, on April 18, said core Internet business grew net revenue 23 percent in the first quarter, softening the effect of a sharp decline in its Motorola mobile phone division.

Get Complete Insight About GOOG?s Earnings Here http://cheapstocks.us/index-lp2-aw.php?code=GOOG (OR Just copy and paste the link)

The company reported a first-quarter profit of $3.35 billion, or $9.94 a share, compared with a profit of $2.89 billion, or $8.75 a share, for the year-earlier period. Adjusted revenue was $11.01 billion, compared with $8.14 billion in the same quarter the previous year. Adjusted profit was $11.58 a share. Analysts on average were expecting the company to report a profit of $10.65 a share, on revenue of $11.12 billion.

About cheapstocks.us
CheapStocks.us is a subscription-based investment newsletter that provides regular coverage, analysis, and commentary on Nasdaq, Pink Sheets and OTCBB Stocks. Subscribers receive intra-day stock analysis and commentary, as well as access to our regular Special Reports, and Trading Tools.

Disclaimer
Cheapstocks.us is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Cheapstocks.us is a wholly owned entity of a financial public relations firm. We have not been compensated by any of the companies listed in this news release.
Contacts:
cheapstocks.us
1419 Westwood Blvd Los
Angeles, CA
90024-4911
staff@cheapstocks.us


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VIVUS, INC.
09/28 VIVUS INC : Change in Directors or Principal Officers (form 8-K)
09/06 VIVUS INC : Entry into a Material Definitive Agreement, Termination of a Materia..
08/29 VIVUS INC : Termination of a Material Definitive Agreement, Regulation FD Disclo..
08/29 VIVUS : Extends Return Date of STENDRA Commercial Rights
08/18 VIVUS : Biotech Stocks on Investors' Radar -- Illumina, XOMA, Lexicon Pharma, an..
08/09 VIVUS INC : Results of Operations and Financial Condition, Financial Statements ..
08/04 VIVUS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
08/04 VIVUS : reports 2Q loss
08/04 VIVUS INC : Results of Operations and Financial Condition, Financial Statements ..
08/04 VIVUS : Reports 2016 Second Quarter Financial Results
More news
Sector news : Biopharmaceuticals
07:26aDJNovo Nordisk Announces Job Cuts
09/29DJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
09/29DJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
More sector news : Biopharmaceuticals
News from SeekingAlpha
09/28 Obalon Therapeutics IPO May Inflate Company Prospects
09/26 Midday Gainers / Losers
09/07 Vivus Extends Date To Accept Back Stendra, Again... What Investors Need To Co..
09/01 Orexigen Inks Contrave Deal For Canada - Why Street Reaction Is Muted
08/26 ZAFGEN : Too Cheap To Ignore
Advertisement
Financials ($)
Sales 2016 81,2 M
EBIT 2016 -28,0 M
Net income 2016 -55,0 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 1,45x
Capi. / Sales 2017 0,83x
Capitalization 118 M
More Financials
Chart VIVUS, INC.
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | VVUS | US9285511005 | 4-Traders
Full-screen chart
Technical analysis trends VIVUS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 10,4 $
Spread / Average Target 820%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Seth H. Z. Fischer Chief Executive Officer & Director
Mark K. Oki Chief Financial & Accounting Officer
Santosh T. Varghese Chief Medical Officer
Jorge Plutzky Independent Director
David York Norton Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.10.78%118
CSL LIMITED3.38%37 825
ALEXION PHARMACEUTICAL..-37.06%26 923
GRIFOLS SA-9.50%13 411
3SBIO INC-18.52%2 876
JIANGXI BOYA BIO-PHARM..--.--%2 629
More Results